骨髓增生异常综合征可起源于多能祖细胞区室。 - Suppr

Myelodysplastic syndrome can propagate from the multipotent progenitor compartment.

作者信息

Rouault-Pierre Kevin, Smith Alexander E, Mian Syed A, Pizzitola Irene, Kulasekararaj Austin G, Mufti Ghulam J, Bonnet Dominique

机构信息

Haematopoietic Stem Cell Laboratory, The Francis Crick Institute, Department of Haematological Medicine, London, UK.

Kings College Hospital, Department of Haematology, Department of Haematological Medicine, London, UK.

出版信息

Haematologica. 2017 Jan;102(1):e7-e10. doi: 10.3324/haematol.2016.152520. Epub 2016 Oct 6.

DOI:10.3324/haematol.2016.152520

PMID:27758823

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5210239/

Abstract

摘要

相似文献

Myelodysplastic syndrome can propagate from the multipotent progenitor compartment.

Haematologica. 2017 Jan;102(1):e7-e10. doi: 10.3324/haematol.2016.152520. Epub 2016 Oct 6.

What is the role of the microenvironment in MDS?

Best Pract Res Clin Haematol. 2019 Dec;32(4):101113. doi: 10.1016/j.beha.2019.101113. Epub 2019 Oct 28.

Beyond the Niche: Myelodysplastic Syndrome Topobiology in the Laboratory and in the Clinic.

Int J Mol Sci. 2016 Apr 13;17(4):553. doi: 10.3390/ijms17040553.

An abnormal secretion of soluble mediators contributes to the hematopoietic-niche dysfunction in low-risk myelodysplastic syndrome.

Blood Cancer J. 2015 Nov 27;5(11):e370. doi: 10.1038/bcj.2015.97.

Bone marrow niche in the myelodysplastic syndromes.

Leuk Res. 2015 Oct;39(10):1020-7. doi: 10.1016/j.leukres.2015.06.017. Epub 2015 Jul 14.

Effects of rigosertib on the osteo-hematopoietic niche in myelodysplastic syndromes.

Ann Hematol. 2019 Sep;98(9):2063-2072. doi: 10.1007/s00277-019-03756-1. Epub 2019 Jul 16.

Chronic myelomonocytic leukemia: Forefront of the field in 2015.

Crit Rev Oncol Hematol. 2015 Aug;95(2):222-42. doi: 10.1016/j.critrevonc.2015.03.002. Epub 2015 Mar 14.

Mast cell growth factor (c-kit ligand) restores growth of multipotent progenitors in myelodysplastic syndrome.

Leukemia. 1994 May;8(5):827-32.

Multipotent stem cell origin of myelodysplastic syndromes.

Blood. 1989 Jun;73(8):2230.

Mesenchymal Stem and Progenitor Cells in Normal and Dysplastic Hematopoiesis-Masters of Survival and Clonality?

Int J Mol Sci. 2016 Jun 27;17(7):1009. doi: 10.3390/ijms17071009.

引用本文的文献

Low-risk MDS-A spotlight on precision medicine for mutated patients.

Hemasphere. 2025 Mar 21;9(3):e70103. doi: 10.1002/hem3.70103. eCollection 2025 Mar.

Myelodysplastic syndromes are multiclonal diseases derived from hematopoietic stem and progenitor cells.

Exp Hematol Oncol. 2022 May 16;11(1):28. doi: 10.1186/s40164-022-00280-3.

Molecular Targeted Therapy and Immunotherapy for Myelodysplastic Syndrome.

Int J Mol Sci. 2021 Sep 23;22(19):10232. doi: 10.3390/ijms221910232.

Engraftment characterization of risk-stratified AML in NSGS mice.

Blood Adv. 2021 Dec 14;5(23):4842-4854. doi: 10.1182/bloodadvances.2020003958.

Nature or Nurture? Role of the Bone Marrow Microenvironment in the Genesis and Maintenance of Myelodysplastic Syndromes.

Cancers (Basel). 2021 Aug 16;13(16):4116. doi: 10.3390/cancers13164116.

NSG-S mice for acute myeloid leukemia, yes. For myelodysplastic syndrome, no.

Haematologica. 2018 Jun;103(6):921-923. doi: 10.3324/haematol.2018.193847.

Modeling the human bone marrow niche in mice: From host bone marrow engraftment to bioengineering approaches.

J Exp Med. 2018 Mar 5;215(3):729-743. doi: 10.1084/jem.20172139. Epub 2018 Feb 16.

Mapping the CLEC12A expression on myeloid progenitors in normal bone marrow; implications for understanding CLEC12A-related cancer stem cell biology.

J Cell Mol Med. 2018 Apr;22(4):2311-2318. doi: 10.1111/jcmm.13519. Epub 2018 Feb 7.

Acute myeloid leukemia xenograft success prediction: Saving time.

Exp Hematol. 2018 Mar;59:66-71.e4. doi: 10.1016/j.exphem.2017.12.002. Epub 2017 Dec 15.

Preclinical modeling of myelodysplastic syndromes.

Leukemia. 2017 Dec;31(12):2702-2708. doi: 10.1038/leu.2017.172. Epub 2017 Jun 2.

本文引用的文献

Mutational hierarchies in myelodysplastic syndromes dynamically adapt and evolve upon therapy response and failure.

Blood. 2016 Sep 1;128(9):1246-59. doi: 10.1182/blood-2015-11-679167. Epub 2016 Jun 6.

SF3B1 mutant MDS-initiating cells may arise from the haematopoietic stem cell compartment.

Nat Commun. 2015 Dec 8;6:10004. doi: 10.1038/ncomms10004.

Genetics factors associated with myelodysplastic syndromes.

Blood Cells Mol Dis. 2015 Jun;55(1):76-81. doi: 10.1016/j.bcmd.2015.04.003. Epub 2015 Apr 17.

Xenograft models for normal and malignant stem cells.

Blood. 2015 Apr 23;125(17):2630-40. doi: 10.1182/blood-2014-11-570218. Epub 2015 Mar 11.

MDS is a stem cell disorder after all.

Cancer Cell. 2014 Jun 16;25(6):713-4. doi: 10.1016/j.ccr.2014.06.001.

Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo.

Cancer Cell. 2014 Jun 16;25(6):794-808. doi: 10.1016/j.ccr.2014.03.036. Epub 2014 May 15.

Myelodysplastic cells in patients reprogram mesenchymal stromal cells to establish a transplantable stem cell niche disease unit.

Cell Stem Cell. 2014 Jun 5;14(6):824-37. doi: 10.1016/j.stem.2014.02.014. Epub 2014 Apr 3.

Clinical effect of point mutations in myelodysplastic syndromes.

N Engl J Med. 2011 Jun 30;364(26):2496-506. doi: 10.1056/NEJMoa1013343.

ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia.

Br J Haematol. 2010 Nov;151(4):365-75. doi: 10.1111/j.1365-2141.2010.08381.x. Epub 2010 Sep 29.

Involvement and functional impairment of the CD34(+)CD38(-)Thy-1(+) hematopoietic stem cell pool in myelodysplastic syndromes with trisomy 8.

Blood. 2002 Jul 1;100(1):259-67. doi: 10.1182/blood-2001-12-0188.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Myelodysplastic syndrome can propagate from the multipotent progenitor compartment.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献